{
  "docId": "019de512-188f-75bd-b9c3-b699923bd74c",
  "docSlug": "b87a8eceb8fdc0b05f41052c19d68b16",
  "documentTitle": "Adagio Therapeutics | Investor Conference Presentation Deck | 19 slides",
  "authorId": "adagio-therapeutics",
  "authorName": "Adagio Therapeutics",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 7,
  "pageCount": 19,
  "prevPage": 6,
  "nextPage": 8,
  "slideType": "comparison_table",
  "function": "compare_peers",
  "density": "dense",
  "nDataPoints": 8,
  "notes": "The slide uses a heatmap to visualize IC50 values, where red indicates higher potency (lower IC50).",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de512-188f-75bd-b9c3-b699923bd74c/7",
  "deckHref": "/decks/019de512-188f-75bd-b9c3-b699923bd74c",
  "deckJsonHref": "/decks/019de512-188f-75bd-b9c3-b699923bd74c.json",
  "deckAnchorHref": "/decks/019de512-188f-75bd-b9c3-b699923bd74c#slide-7",
  "components": [
    {
      "bbox": {
        "h": 0.5,
        "w": 0.15,
        "x": 0.2,
        "y": 0.2
      },
      "kind": "chart",
      "text": "Heatmap of IC50 values for various antibodies against the Victoria variant",
      "attrs": null,
      "subkind": "heatmap",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e0df6d02-fee2-41e3-934d-8eff464f3514",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.1,
        "x": 0.83,
        "y": 0.23
      },
      "kind": "chart",
      "text": "IC50 (µg/ml) scale: <0.02 (red) to >10 (grey)",
      "attrs": null,
      "subkind": "legend",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "310e59b2-d2ef-4f1c-b41b-29ed8f3c5641",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.8,
        "x": 0.05,
        "y": 0.85
      },
      "kind": "disclaimer",
      "text": "There are no head-to-head trials between ADG20 and the other products referenced on this slide. No comparisons can be made between product efficacy or safety. ADG20 is an investigational therapy that is not approved for use in any country.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "290e6042-6cff-49ab-abc2-f7244ebffec7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.15,
        "x": 0.05,
        "y": 0.25
      },
      "kind": "image",
      "text": "Company logos for GSK, VIR, Regeneron, Lilly, AstraZeneca",
      "attrs": null,
      "subkind": "logo-grid",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b7f9a8d0-84a3-4a9b-835d-a91ca0b69a6c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.05,
        "y": 0.1
      },
      "kind": "title",
      "text": "ADG20 shows broad yet variable neutralizing activity against all variants of concern",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fe724083-c4ae-4b1c-8d0d-3df851d429af",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "In vitro neutralization of antibodies in clinical development versus variants of concern",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "415564bc-b6db-4754-bda6-b80b6be9f175",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "comparison_frame",
      "slug": null,
      "matchId": "59409f39-d0ad-41e7-b5f5-cec29b49ba8f",
      "evidence": "Comparison of ADG20 against competitor antibodies in a standardized assay",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 14,
      "from": 5,
      "beatId": "6a1a205b-c7b3-4004-94f2-1eab1f50d86f",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Agitate (Make it worse)",
      "beatSlug": "problem-agitate-solution-agitate-make-it-worse",
      "evidence": "The document agitates the problem through multiple tables and data points, highlighting the challenge of COVID-19 variants.",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Development",
      "parentBeatSlug": "development"
    }
  ],
  "loops": [
    {
      "to": 14,
      "from": 4,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "367a8c0e-d39d-4694-aace-945e8b5a0e36",
      "evidence": "The document implies the cost of inaction through its emphasis on the challenge of COVID-19 variants and the need for effective treatments.",
      "position": 0,
      "objective": "What is the cost of inaction in addressing COVID-19 variants?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}